Orthofix Medical Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Massimo Calafiore

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	0.08%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	1.6yrs

Son yönetim güncellemeleri

Recent updates

CEO

Massimo Calafiore (52 yo)

less than a year

Görev süresi

Mr. Massimo Calafiore is President, CEO & Director of Orthofix Medical Inc. from January 8, 2024 and as Interim President of Global Spine from January 10, 2024. Mr. Massimo Calafiore was the Chief Executiv...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Gillespie	VP & Corporate Controller	3.7yrs	US$887.05k	0.0088% € 59.3k
Massimo Calafiore	President	less than a year	Veri yok	0.079% € 530.9k
Julie Andrews	Chief Financial Officer	less than a year	Veri yok	Veri yok
Aviva McPherron	President of Global Operations & Quality	less than a year	Veri yok	Veri yok
Julie Dewey	Chief Investor Relations & Communications Officer	less than a year	Veri yok	Veri yok
Jill Mason	Chief Compliance & Risk Officer	no data	Veri yok	Veri yok
J. Cedron	Chief Legal Officer & Corporate Secretary	less than a year	Veri yok	Veri yok
Stephanie Walsh	Chief Human Resources Officer	less than a year	Veri yok	Veri yok
Ehab Esmail	Senior Vice President of Global Quality	6yrs	Veri yok	Veri yok
Tyler Lipschultz	President of Global Biologics	2yrs	Veri yok	Veri yok
Beau Standish	President of Global Enabling Technologies	no data	Veri yok	Veri yok
Lucas Vitale	Chief People & Business Operations Officer	less than a year	Veri yok	Veri yok

0.9yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim: OM2 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.9 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Massimo Calafiore	President	less than a year	Veri yok	0.079% € 530.9k
John Henneman	Independent Director	2yrs	US$355.42k	0.090% € 607.0k
Alan Bazaar	Independent Director	1.1yrs	US$300.00k	0% € 0
Jason Hannon	Independent Director	4.6yrs	US$376.25k	0.012% € 80.7k
Charles Kummeth	Independent Director	1.1yrs	US$300.00k	0.039% € 264.6k
Michael Finegan	Independent Chair of the Board	1.1yrs	US$300.00k	0% € 0
Michael Paolucci	Independent Director	8.8yrs	US$376.25k	0.032% € 212.8k
Shweta Maniar	Independent Director	2yrs	US$355.42k	0.015% € 101.0k
Wayne Burris	Independent Director	1.6yrs	US$539.70k	0.017% € 112.6k

1.6yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OM2 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/20 19:07
Gün Sonu Hisse Fiyatı	2025/01/17 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Orthofix Medical Inc. 19 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Gregory Chodaczek	Boenning & Scattergood, Inc.
Michael Gorman	BTIG
William Plovanic	Canaccord Genuity

Orthofix Medical Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Recent updates

Third quarter 2024 earnings released: US$0.71 loss per share (vs US$0.78 loss in 3Q 2023)

Orthofix Medical Inc. Reiterates Earnings Guidance for Full Year 2024

Levi & Korsinsky, LLP Notifies Investors in Orthofix Medical Inc. of A Class Action Securities Law

Orthofix Medical Inc. to Report Q3, 2024 Results on Nov 07, 2024

Bronstein, Gewirtz & Grossman, LLC Files Lawsuit Against Orthofix Medical Inc. and Seaspine Holdings Corporation

No longer forecast to breakeven

Scott+Scott Attorneys At Law LLP Files Securities Class Action Lawsuit in the United States District Court for the Eastern District of Texas Against Orthofix Medical, Inc

Patrick Fisher Joins Orthofix as President of Global Orthopedics Business

New minor risk - Share price stability

Second quarter 2024 earnings released: US$0.88 loss per share (vs US$1.07 loss in 2Q 2023)

Orthofix Medical Inc. Revises Revenue Guidance for the Full Year 2024

Orthofix Names Stephanie Walsh as Chief Human Resources Officer

Orthofix Medical Inc. to Report Q2, 2024 Results on Aug 06, 2024

Orthofix Medical Inc. Announces First Implant of Fitbone Transport and Lengthening System

Orthofix Medical Inc.(NasdaqGS:OFIX) dropped from Russell 2000 Value-Defensive Index

Orthofix Medical Inc. Appoints Michael Finegan as Chair of Board of Directors

Orthofix Medical Inc. Appoints Aviva Mcpherron as President of Global Operations and Quality

Orthofix Medical Inc. Appoints Max Reinhardt as President of Global Spine Business Effective June 10, 2024

Orthofix Medical Inc. Announces FDA 510(K) Clearance for the Rodeo Telescopic Nail

Orthofix Medical Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings released: US$0.95 loss per share (vs US$1.71 loss in 1Q 2023)

Orthofix Medical Inc., Annual General Meeting, Jun 18, 2024

Orthofix Medical Inc. to Report Q1, 2024 Results on May 07, 2024

Orthofix Medical Inc. Appoints Andres Cedron as New Chief Legal Officer

New minor risk - Profitability

Orthofix Medical Inc. Announces Board Resignation

Orthofix Medical Inc. Appoints Lucas Vitale as Chief People and Business Operations Officer

Full year 2023 earnings released: US$4.12 loss per share (vs US$0.98 loss in FY 2022)

Orthofix Medical Inc. Provides Earnings Guidance for the Year 2024

Orthofix Medical Inc. to Report Q4, 2023 Results on Mar 05, 2024

Orthofix Medical Inc. Names Massimo Calafiore as President and Member of the Board of Directors Effective Immediately

Orthofix Medical Inc. Appoints Julie Andrews as Chief Financial Officer

Orthofix Announces Publication of New Data Supporting Use of PEMF Stimulation in Lumbar Spine Fusion Procedures for Patients at Risk of Pseudarthrosis

Orthofix Medical Inc. Announces Board Changes

Orthofix Medical Inc. Appoints Massimo Calafiore as Chief Executive Officer, Effective in Early 2024

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Third quarter 2023 earnings released: US$0.78 loss per share (vs US$0.53 loss in 3Q 2022)

Orthofix Medical Inc. Announces Full Commercial Launch of the Waveform L Interbody System for Lateral Lumbar Fusion Procedures

Orthofix Medical Inc. to Report Q3, 2023 Results on Nov 08, 2023

Orthofix Medical Inc. Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for Use in Spine and Orthopedic Procedures

Orthofix Medical Inc. Announces First Patient Procedures and Full Commercial Launch of the Galaxy Fixation Gemini System and Expanded Sterile Kit Offerings for Orthopedic Trauma Procedures

Independent Director recently bought €95k worth of stock

Orthofix Medical Inc. Announces Management Appointments

Orthofix Medical Inc. Announces Management Changes

Second quarter 2023 earnings released: US$1.07 loss per share (vs US$0.12 profit in 2Q 2022)

Orthofix Medical Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Orthofix Medical Inc. to Report Q2, 2023 Results on Aug 08, 2023

Orthofix Medical Inc. Introduces New Phantom and Tornado Hins for Truelok Ring Fixation Systems

Orthofix Medical Inc. Announces Changes to Board of Directors

Orthofix Medical Inc Announces the Full Commercial Launch of WaveForm A 3D Printed Anterior Lumbar Interbody

Orthofix Medical Inc. Announces First Presentation of Seven-Year Outcome Data for the M6-C Artificial Cervical Disc with Other Clinical and Scientific Abstracts At the Isass Annual Meeting

President of Global Spine Business recently sold €146k worth of stock

First quarter 2023 earnings released: US$1.71 loss per share (vs US$0.22 loss in 1Q 2022)

Orthofix Medical Inc. Revises Sales Guidance for the Year 2023

Full year 2022 earnings released: US$0.98 loss per share (vs US$1.95 loss in FY 2021)

High number of new directors

Orthofix Announces Full Commercial Launch and First Patient Cases of Mariner Deformity System

Orthofix Medical Inc. Provides Unaudited Preliminary Net Sales Results Fourth Quarter and Full Year Ended December 31, 2022

Orthofix Medical Inc. Announces CFO Changes

Orthofix Medical Inc. Announces Publication of Data Demonstrating the Clinical Benefits of Trinity Elite Cellular Bone Allograft in Lumbar Fusion Procedures

Two unknown private equity fund sponsors submitted a non-binding indication of interest to acquire Orthofix Medical Inc. (NasdaqGS:OFIX) for approximately $460 million.

Orthofix and SeaSpine Announce John Bostjancic to Serve as CFO for Combined Company Post Closing

High number of new directors

Third quarter 2022 earnings released

Orthofix Medical Inc. Provides Financial Guidance for the Full Year 2022

Orthofix Medical Inc. to Report Q3, 2022 Results on Nov 03, 2022

Orthofix Announces First Patient Implants with Legacy Demineralized Bone Matrix for Spine, Pelvic and Extremities Procedures

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.

Orthofix Medical Inc. (NasdaqGS:OFIX) entered into a definitive agreement to acquire SeaSpine Holdings Corporation (NasdaqGS:SPNE) for approximately $280 million in a merger of equals transaction.